Breakfast Technical Briefing on Drug Makers Stocks -- Amarin, Endo, Ionis Pharma, and Teva Pharma

Wednesday, October 4, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 4, 2017 /PRNewswire/ --

If you want a Stock Review on AMRN, ENDP, IONS, or TEVA then come over

to and sign up for your free customized report. This morning, redirects investors' attention to the Drug Manufacturers space, which includes companies that manufacture and process pharmaceutical
products. Equities under assessment today are: Amarin Corp. PLC (NASDAQ: AMRN), Endo International PLC (NASDAQ: ENDP), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Daily Stock Tracker published free research reports on these stocks today at:


Dublin, Ireland-based Amarin Corp. PLC's shares declined 0.57%, closing Tuesday's trading session at $3.47. The stock recorded a trading volume of 823,054 shares. The Company's shares have advanced 6.77% in the last month and 12.66% since the start of this year. The stock is trading 3.05% above its 50-day moving average and 6.22% above its 200-day moving average. Additionally, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have a Relative Strength Index (RSI) of 54.50.  

On September 13th, 2017, Amarin announced that Mark W. Salyer has joined the Company as Chief Commercial Officer. In this newly created position, Mr. Salyer will work to build on the Company's recent revenue growth and lead future global commercial expansion plans and execution, particularly related to the anticipated landmark REDUCE-IT cardiovascular outcomes trial results. See our free and comprehensive research report on AMRN at:

Endo International 

On Tuesday, shares in Dublin, Ireland headquartered Endo International PLC recorded a trading volume of 8.35 million shares, which was above their three months average volume of 5.83 million shares. The stock dropped 4.18%, ending the day at $8.71. The Company's shares have advanced 0.81% in the past month. The stock is trading below its 50-day moving average by 3.47%. Furthermore, shares of Endo, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have an RSI of 49.17.  

On September 26th, 2017, Endo announced that four-time PGA TOUR winner Tim Herron is teaming up with its subsidiary Endo Pharmaceuticals Inc.; Damon Adamany, MD of The CORE Institute; and the Facts on Hand campaign to educate adults about one of the more common hand conditions. The campaign is raising awareness of Dupuytren's Contracture, a progressive, potentially disfiguring hand condition.

On September 28th, 2017, research firm Goldman initiated a 'Sell' rating on the Company's stock, with a target price of $7 per share. ENDP free research report is just a click away at:

Ionis Pharmaceuticals 

Carlsbad, California headquartered Ionis Pharmaceuticals Inc.'s stock finished the day 0.42% lower at $52.69 with a total trading volume of 899,170 shares. The Company's shares have advanced 10.16% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.07% and 9.41%, respectively. Additionally, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 46.83.  

On September 12th, 2017, Akcea Therapeutics, Inc., an affiliate of Ionis Pharma, announced the filing of a New Drug Submission (NDS) to Health Canada for volanesorsen, an investigational medicine for the treatment of familial chylomicronemia syndrome. Health Canada has also granted priority review for the volanesorsen NDS. Sign up for your complimentary report on IONS at:

Teva Pharmaceutical Industries 

Shares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd ended yesterday's session 1.89% higher at $18.82. The stock recorded a trading volume of 22.25 million shares, which was above its three months average volume of 21.20 million shares. The Company's shares have advanced 18.36% in the last one month. The stock is trading 4.62% below its 50-day moving average. Moreover, shares of Teva Pharma, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have an RSI of 59.37.  

On September 21st, 2017, research firm Bernstein reiterated its 'Market Perform' rating on the Company's stock with a decrease of the target price from $28 a share to $20 a share.

On September 25th, 2017, Teva Pharma announced the reintroduction of the generic equivalent to Depo-Provera®1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP), 150 mg/mL, in the US. Medroxyprogesterone acetate injectable suspension is a progestin indicated only for the prevention of pregnancy. Register for free on and download the latest research report on TEVA at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store